Pregnancy outcome in idiopathic inflammatory myopathy.
The aim of our study was to assess the prevalence and outcome of pregnancy in idiopathic inflammatory myopathy patients who became pregnant after the onset of the disease. Female idiopathic inflammatory myopathy patients (173) were included in our study. The patients' charts and clinical data were retrospectively analyzed. One hundred and four female idiopathic inflammatory myopathy patients had 186 pregnancies, but only nine of these patients (4 polymyositis-PM, 5 dermatomyositis-DM) became pregnant after the onset of the disease. Nine patients with pregnancies after the disease onset had 14 gravidities. Six pregnancies resulted in normal deliveries, two ended in prematurity, six ended in abortions (two induced abortions). Regarding the four patients (3 PM, 1 DM) with active disease at the time of pregnancy, two pregnancies ended in prematurity, four ended in spontaneous abortion and one healthy baby delivered. The other five patients (2 PM, 3 DM) with the disease in remission had uneventful pregnancies and healthy babies were delivered. Treatment was not required during pregnancy in case of two dermatomyositis patients with long lasting remission. New onset dermatomyositis developed in one patient in her pregnancy's third trimester. The mean weight of newborns in the active myositis cases was 2,193 (1,680-2,700) g; while in patients with remission was 3,167 (2,800-3,800) g. The active maternal disease in idiopathic inflammatory myopathy (IIM) might result intrauterin retardation and death. Disease activity in active and new-onset cases could be controlled by increasing the dose of corticosteroid.
Váncsa
A
A
Division of Clinical Immunology, Third Department of Internal Medicine, Institute of Medicine, University of Debrecen, Hungary.
Ponyi
A
A
Constantin
T
T
Zeher
M
M
Dankó
K
K
D000022:Abortion, Spontaneous; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D050498:Live Birth; D008775:Methylprednisolone / Q000627:therapeutic use; D017285:Polymyositis / Q000150:complications* / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D047928:Premature Birth; D012189:Retrospective Studies
D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone